Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8954062 | 0.89 | TP53 (0.47) | TP53 | |
| SCHEMBL8954158 | 0.88 | TP53 (0.48) | TP53 | |
| Hydrochloric Acid SCHEMBL8954315 | 0.87 | TP53 (0.48) | TP53 | |
| SCHEMBL8954170 | 0.87 | TP53 (0.46) | TP53 | |
| SCHEMBL8954114 | 0.87 | TP53 (0.47) | TP53 | |
| SCHEMBL7060199 | 0.86 | TP53 (0.57) | TP53 | |
| SCHEMBL7059041 | 0.85 | TP53 (0.45) | TP53 | |
| SCHEMBL8957023 | 0.84 | TP53 (0.45) | TP53 | |
| SCHEMBL8957028 | 0.84 | TP53 (0.45) | TP53 | |
| SCHEMBL9473192 | 0.84 | CCR2 (0.45) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.L.C. | 2002-09-12 | — | — | US | disclosed |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2002-07-04 | — | — | US | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0437103-A2 | Substituted 5-(alkyl)carboxamide imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| EP-0425211-A1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | TP53 3913/4885PTGDR2 65/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | TP53 4866/4885PTGDR2 275/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | TP53 3163/4885PTGDR2 287/4885 |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | AGTR2, AGTR1, VIPR2 | TP53 4583/4885PTGDR2 93/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | TP53 3514/4885PTGDR2 240/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | TP53 3432/4885PTGDR2 671/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | TP53 3163/4885PTGDR2 287/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | TP53 3465/4885PTGDR2 118/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | TP53 3913/4885PTGDR2 65/4885 |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, REN | TP53 4799/4885PTGDR2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.